Sphingomyelin/cholesterol liposomal vincristine: A new formulation for an old drug

Expert Opinion on Biological Therapy

Volumn 6, Issue 4, 2006, Pages 409-415

  Boehlke, Larry ^b   Winter, Jane N ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

Liposome; Non Hodgkin's lymphoma; Sphingosomal vincristine; Vincristine

Indexed keywords

CHOLESTEROL; DEXAMETHASONE; RITUXIMAB; SPHINGOMYELIN; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; HUMAN; LARGE CELL LYMPHOMA; META ANALYSIS; NEUROTOXICITY; NONHODGKIN LYMPHOMA; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMISTRY, PHARMACEUTICAL; CHOLESTEROL; DRUGS, INVESTIGATIONAL; HUMANS; LIPOSOMES; SPHINGOMYELINS; VINCRISTINE;

EID: 33645779671     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.4.409     Document Type: Review

References (33)

1. HARRIS NL, JAFFE ES, DIEBOLD J et al.: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J. Clin. Oncol. (1999) 17(12):3835-3849.
2. HAHN T, WOLFF SN, CZUCZMAN M et al.: The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large cell B-cell non-Hodgkin's lymphoma. Biol. Blood Marrow Transplant. (2003) 9(10):667.
3. PHILIP T, GUGLIELMI C, HAGENBEEK A et al.: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N. Engl. J. Med. (1995) 333(23):1540-1545.
4. WEBB M, SALTMAN D, CONNORS J, GOLDIE J: A literature review of single agent treatment of multiply relapsed aggressive non-Hodgkin's lymphoma. Leuk. Lymphoma (2002) 43:975-982.
5. MORSCHHAUSER F, HUGLO D, MARTINELLI G et al.: Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: results of an open-label Phase II trial. Blood (2004) 104:41a.
6. OWELLEN RJ, HARTKE CA, DICKERSON RM, HAINS FO: Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class. Cancer Res. (1976) 36(4):1499-1502.
7. BOMAN N, BALLY B, CULLIS P, MAYER LD: Encapsulation of vincristine in liposomes reduces its toxicity and improves its antitumor efficacy. J. Liposome Res. (1995) 5:523-541.
8. MAYER LD, MASIN D, NAYAR R, BOMAN NL, BALLY MB: Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. Br. J. Cancer (1995) 71(3):482-488.
9. HORTON JK, HOUGHTON PJ, HOUGHTON JA: Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem. Pharmacol. (1988) 37(20):3995-4000.
10. WEIDEN PL, WRIGHT SE: Vincristine neurotoxicity. N. Engl. J. Med. (1972) 286(25):1369-1370.
11. CUTTING HO: Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy. Am. J. Med. (1971) 51(2):269-271.
12. CARDE P, MACINTOSH F, ROSENBERG S: A dose and time response analysis of the treatment of Hodgkins disease with MOPP chemotherapy. J. Clin. Oncol. (1983) 1:146-153.
13. HAIM N, EPELBAUM R, BEN-SHAHAR M, YARNITSKY D, SIMRI W, ROBINSON E: Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer (1994) 73(10):2515-2519.
14. FELNEROVA D, VIRET JF, GLUCK R, MOSER C: Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr. Opin. Biotechnol. (2004) 15(6):518-529.
15. GABIZON A, GOREN D, COHEN R, BARENHOLZ Y: Development of liposomal anthracyclines: from basics to clinical applications. J. Control. Release (1998) 53(1-3):275-279.
16. WEBB M, HARASYM T, MASIN D, BALLY M, MAYER L: Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br. J. Cancer (1995) 72:896-904.
17. WEBB MS, LOGAN P, KANTER PM et al.: Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother. Pharmacol. (1998) 42(6):461-470.
18. EMBREE L, GELMON K, TOLCHER A et al.: Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother. Pharmacol. (1998) 41(5):347-352.
19. YUAN F, DELLIAN M, FUKUMURA D et al.: Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. (1995) 55(17):3752-3756.
20. YUAN F, LEUNIG M, HUANG S, BERK DA, PAPAHADJOPOULOS D, JAIN R: Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. (1994) 54(13):3352-3356.
21. KRISHNA R, WEBB M, ST ONGE G, MAYER L: Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J. Pharmacol. Exp. Ther. (2001) 298:1206-1212.
22. GELMON KA, TOLCHER A, DIAB AR et al.: Phase I study of liposomal vincristine. J. Clin. Oncol. (1999) 17(2):697-705.
23. THOMAS DA, GARCIA-MANERO G, FADERL S et al.: Preliminary results of Phase I trial of sphingosomal vincristine (SV) and dexamethasone in relapsed or refractory acute lymphocytic leukemia (ALL). Blood (2004) 104(11):748A (abstract #2735).
24. SARRIS AH, HAGEMEISTER F, ROMAGUERA J et al.: Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing Phase II trial. Ann. Oncol. (2000) 11(1):69-72.
25. SARRIS A, ROMAGUERA F, HAGEMEISTER F et al.: Liposomal vincristine: a Phase II trial in relapsed or refractory non-Hodgkin's lymphomas (NHL) (abstr). Blood (1999) 10:94a.
26. WINTER J: Investigators of the PIVOTAL Multicenter Study Group. Multiply relapsed diffuse, aggressive non-Hodgkin's lymphoma (NHL) patients respond to single agent sphingosomal vincristine (abstr). Blood (2003) 11:638a.
27. RODRIGUEZ M, WINTER J: Treatment response to single agent Sphingosomal Vincristine in patients with relapsed and/or refractory diffuse aggressive non-Hodgkin's lymphoma (NHL): subgroup analyses (abstr). Blood (2004) 104:682a.
28. GOY A, HART S, PAZ TIONGSON L et al.: Preliminary report of a Phase II study of vincristine sulfate liposomes injection (VSLI) in patients with relapsed or refractory Hodgkin's disease (abstr). Blood (2003) 102:640a.
29. THOMAS DA, SARRIS AH, CORTES J et al.: Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer (2006) 106(1):120-127.
30. RODRIGUEZ MA, DANG N, FAYAD L et al.: Phase II study of sphingosomal vincristine in CHOP+/- rixtuximab for patients with aggressive non-Hodgkin's lymphoma (NHL): promising 3 year follow-up results in elderly patients. Session type: Poster Session 101-1. Blood (2005) 106(11):493a.
31. ASHCROFT A, KAPLAN L, DAMON L, MORGAN GJ: Sphingosomal vincristine plus rituximab for treatment of large B-cell lymphoma. Blood (2003) 102:400a.
32. ONCOLOGIC DRUGS ADVISORY COMMITTEE BRIEFING DOCUMENT: Marqibo® (vincristine sulfate liposomes injection) indication: treatment of patients with aggressive non-Hodgkin's Lymphoma previously treated with at least two combination chemotherapy regimens. (1 December 2004). FDA Review (2004-4084 B1_04_FDA-Margibo.pdf) (NDA 21-600).
33. WINTER JN, WELLER EA, HORNING SJ et al.: Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood (2006) (In Press).